Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
NEW YORK, May 01, 2018 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akorn, Inc. (NASDAQ:AKRX) from March 1, 2017 through February 26, 2018, both dates inclusive (“Class Period”) of the important May 7, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Akorn investors under the federal securities laws.
To join the Akorn class action, go to http://www.rosenlegal.com/cases-1301.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Akorn’s failure to comply with FDA data integrity requirements would jeopardize Fresenius’s acquisition of Akorn; (2) Akorn lacked effective internal controls over financial reporting; and (3) as a result, Akorn’s financial statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 7, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1301.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. The Rosen Law Firm was Ranked No. 1 by Institutional Shareholder Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Zachary Halper, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
